International journal of dentistry · 2026
Evaluation of GCF Adiponectin and Resistin Expression Level as an Indicator in Periodontal Staging and Grading After Periodontal Therapy in Class III Obese Patients.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Badr Bahaa Mohammed, Ibrahim Ibrahim Hammad, Ali Abdullah Ibrahim, Hudu Shuaibu Abdullahi, Ali Asmaa Rashad, Kamel Asem Mohammed
Аннотация
BACKGROUND: The current trial aimed to assess the effects of phase I periodontal therapy on gingival crevicular fluid (GCF) adiponectin and resistin levels in obese individuals with varying stages and grades of periodontitis. The feasibility of using adiponectin and resistin in a periodontitis staging and grading classification system was being evaluated.
MATERIALS AND METHODS: This prospective clinical study was carried out on 60 class Ⅲ obese periodontitis patients who were divided equally into group І, first stage, grade B periodontitis; group Ⅱ, second stage, grade B periodontitis; group Ⅲ, third stage, grade B periodontitis; and group Ⅳ, fourth stage, grade C periodontitis. Body mass index (BMI), HbA1c, and periodontal indices were assessed, and GCF was collected and analyzed for adiponectin and resistin, before and 3 months after treatment.
RESULTS: A positive correlation was observed between BMI/HbA1c and periodontal disease stages. After periodontal therapy, adiponectin and resistin levels were obviously affected. In group Ⅲ resistin decreases from 25.68 ± 0.89 to 14.68 ± 1.54 ng/mL, adiponectin rose from 155.8 ± 39.7 to 435.8 ± 49.2 ng/mL. In group Ⅳ, resistin decreased from 53.2 ± 1.1 to 20.3 ± 2.03 ng/mL, and adiponectin increased from 104.41 ± 8.87 to 543.21 ± 36.81 ng/mL. There were no statistically significant correlations between clinical attachment level (CAL) and adiponectin/resistin. In grade B periodontitis, resistin decreased from 17.25 ± 6.1 to 13.5 ± 1.39 ng/mL after periodontal therapy. Adiponectin rose from 257.27 ± 84.26 to 355.61 ± 72.4 ng/mL. In grade C periodontitis, resistin expression was lower, from 53.2 ± 1.1 to 20.37 ± 2.03 ng/mL, whereas adiponectin was elevated from 104.41 ± 8.8 to 543.21 ± 36.81 ng/mL after 3 months of periodontal control treatment.
CONCLUSION: Adiponectin and resistin were significantly affected after periodontal therapy, especially in stage 3 and stage 4 periodontitis. Adiponectin can be used as an intermediary for periodontitis grading.
MATERIALS AND METHODS: This prospective clinical study was carried out on 60 class Ⅲ obese periodontitis patients who were divided equally into group І, first stage, grade B periodontitis; group Ⅱ, second stage, grade B periodontitis; group Ⅲ, third stage, grade B periodontitis; and group Ⅳ, fourth stage, grade C periodontitis. Body mass index (BMI), HbA1c, and periodontal indices were assessed, and GCF was collected and analyzed for adiponectin and resistin, before and 3 months after treatment.
RESULTS: A positive correlation was observed between BMI/HbA1c and periodontal disease stages. After periodontal therapy, adiponectin and resistin levels were obviously affected. In group Ⅲ resistin decreases from 25.68 ± 0.89 to 14.68 ± 1.54 ng/mL, adiponectin rose from 155.8 ± 39.7 to 435.8 ± 49.2 ng/mL. In group Ⅳ, resistin decreased from 53.2 ± 1.1 to 20.3 ± 2.03 ng/mL, and adiponectin increased from 104.41 ± 8.87 to 543.21 ± 36.81 ng/mL. There were no statistically significant correlations between clinical attachment level (CAL) and adiponectin/resistin. In grade B periodontitis, resistin decreased from 17.25 ± 6.1 to 13.5 ± 1.39 ng/mL after periodontal therapy. Adiponectin rose from 257.27 ± 84.26 to 355.61 ± 72.4 ng/mL. In grade C periodontitis, resistin expression was lower, from 53.2 ± 1.1 to 20.37 ± 2.03 ng/mL, whereas adiponectin was elevated from 104.41 ± 8.8 to 543.21 ± 36.81 ng/mL after 3 months of periodontal control treatment.
CONCLUSION: Adiponectin and resistin were significantly affected after periodontal therapy, especially in stage 3 and stage 4 periodontitis. Adiponectin can be used as an intermediary for periodontitis grading.